Cyclacel Pharma (CYCC) Misses Q4 EPS by 12c
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Join SI Premium – FREE
Cyclacel Pharma (NASDAQ: CYCC) reported Q4 EPS of ($0.60), $0.12 worse than the analyst estimate of ($0.48).
For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk and Micron surge as Apple confirms memory price pass-through
- JPMorgan Upgrades SHIFT UP Corp (462870:KS) to Overweight
- Pfizer reaffirms 2026 guidance after CFO transition news
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
